Kavya Kopparapu

Kavya Kopparapu: The Diagnostics Built From a 3D-Printed Lens

Diabetic retinopathy is one of the leading causes of preventable blindness, and screening for it usually requires an ophthalmologist, a specialized retinal camera, and an appointment many patients in poor or rural regions never get. Kavya Kopparapu's answer, built as a high school student in Alexandria, Virginia, was a 3D-printed lens clipped onto a smartphone camera and an artificial-intelligence model trained to read the resulting images. She called it Eyeagnosis, and it was only the first of several diagnostic tools she built before finishing her undergraduate degree.

Thomas Jefferson High School

Kopparapu attended Thomas Jefferson High School for Science and Technology in Alexandria, a magnet school known for producing research-track students, and went on to Harvard University. Her earliest recorded project came in her freshman year: MediKey, a mobile app that let emergency medical technicians securely pull medical information from an unconscious patient's smartphone — a problem with an obvious real-world stakes attached to every second an EMT spends guessing at a patient's allergies or medications.

Eyeagnosis and the Smartphone Retina Exam

In 2016, at age seventeen, Kopparapu built Eyeagnosis: a low-cost 3D-printed lens attachment paired with a mobile app that used machine learning to flag diabetic retinopathy from a smartphone photo of the retina, without the extensive eye exam a conventional diagnosis requires. The project targeted a specific, global access gap — diabetic retinopathy is treatable if caught early, but early screening is exactly the step that is hardest to deliver cheaply at scale. The tool earned her recognition as a WebMD Health Hero in 2017 and coverage across outlets tracking teenage inventors working in applied machine learning.

GlioVision and Faster Cancer Diagnostics

Kopparapu followed Eyeagnosis with GlioVision, a platform developed between 2017 and 2019 for automated assessment of glioblastoma, an aggressive brain cancer, directly from pathology images. The pitch was speed and cost: DNA-based diagnostic methods for glioblastoma are slow and expensive, and an image-based machine learning approach promised a faster, cheaper alternative for classifying tumor samples. The work drew on collaboration with researchers at Stony Brook University and the National Institutes of Health, and eventually contributed to a patent in her name (US10748040B2).

Building the Pipeline Behind Her

Rather than treat her own inventions as the endpoint, Kopparapu founded the GirlsComputingLeague in 2015 to run computing and science workshops for girls in underfunded schools, and later launched a tech-equity initiative in partnership with HP in November 2020. She continued into research roles at Harvard, taking courses such as Tiny Machine Learning and Computing at Scale, interned on Apple's Core Machine Learning team, and was named an AAAS IF/THEN Ambassador for women in STEM starting in 2019. Recognition followed across a wider media register than most teenage inventors receive: a feature in the Smithsonian's "Girlhood (It's Complicated)" exhibit in 2020, a Seventeen Magazine "Voices of the Year" honor, and a spot as a Harvard Undergraduate Technology Innovation Fellow. Of her own motivation, she said: "I want to make an impact on students who want to pursue computer science, and make them more confident in their abilities, skills, and future."

A Public-Facing Scientist

Unlike many teenage inventors whose visibility fades once the science fair trophies stop, Kopparapu kept building a public profile around the work rather than around herself: hosting an Artificial Intelligence Summit in October 2017 that brought industry figures and students into the same room, serving on the board of an interactive science museum, and publishing in WebMD's own AI-focused issue in early 2020. She was also profiled by Marie Claire in September 2020 and recognized by the Alba Botanica "Do Good, Do Beautiful" campaign in April 2019 — the kind of consumer-brand attention that rarely finds its way to a computational biology project, and that suggests her story was being read as much for its advocacy value as for its technical content.

Why Kavya Is Called a Genius

Kopparapu's claim to the word rests on a specific and repeatable pattern rather than a single flash of insight: identifying a diagnostic bottleneck in medicine — retinopathy screening, glioblastoma classification — and building a working machine learning pipeline around cheap, accessible hardware (a smartphone, a 3D-printed attachment) instead of the expensive specialized equipment the field normally assumes is required. That is a genuine feat of applied engineering judgment: knowing which parts of an expensive diagnostic workflow can be replaced by a phone camera and a trained model, and which cannot.

The honest caveat is that neither Eyeagnosis nor GlioVision is documented in the sourced material as having reached clinical deployment or peer-reviewed validation at scale; both are described as prototypes and research collaborations rather than FDA-cleared or hospital-adopted tools. That gap — between a working proof of concept covered by WebMD and Smithsonian and an actual diagnostic product doctors use — is where teenage-inventor coverage often overstates itself, and it applies here too. What is not in question is the pattern: Kopparapu built two distinct diagnostic pipelines before she had a bachelor's degree, and used the platform from the first to fund advocacy work rather than to simply cash in the press coverage.

Legacy

Kopparapu's most durable contribution may turn out to be less any single diagnostic tool than the infrastructure she built around herself and other young women in computing — the GirlsComputingLeague, the IF/THEN ambassadorship, the HP partnership — a track record of converting personal recognition into institutional access for people who didn't have her school, her mentors, or her lab collaborations.